Kazuki Tanaka - Publications

Clinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication.

Journal: Clinical and experimental nephrology

Published: November 24, 2025

Investigation of clinical and genetic characteristics of Alport syndrome using a national registry in Japan (JP-ALPS).

Journal: Clinical and experimental nephrology

Published: April 15, 2025

Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data.

Journal: Blood

Published: November 08, 2024

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

Journal: Kidney medicine

Published: August 06, 2024

Analysis of the ratio of urinary beta-2-microglobulin to total protein concentration in children with isolated tubulointerstitial disease.

Journal: Clinical and experimental nephrology

Published: August 30, 2022

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 21, 2021

Serum albumin level is associated with mycophenolic acid concentration in children with idiopathic nephrotic syndrome.

Journal: European journal of pediatrics

Published: June 08, 2021

Genotype-Phenotype Correlation in WT1 Exon 8 to 9 Missense Variants.

Journal: Kidney international reports

Published: January 27, 2021

Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

Journal: Pediatric nephrology (Berlin, Germany)

Published: December 09, 2020

Management of a Preterm Infant with Renal Tubular Dysgenesis: A Case Report and Review of the Literature.

Journal: The Tohoku journal of experimental medicine

Published: August 21, 2020

Mortality outcomes and clinical background of children on maintenance dialysis without receiving kidney transplantation.

Journal: Clinical and experimental nephrology

Published: July 16, 2020

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

Journal: Pediatric nephrology (Berlin, Germany)

Published: June 30, 2020